VC-backed Curetis prices IPO

The flotation took place on November 11 on Euronext in Amsterdam and Brussels.

The listing, which comprised 4 million ordinary shares priced at €10 apiece, is expected to raise net proceeds of €40m for the company. 

The offering also includes an over-allotment option for 600,000 shares - equivalent to a 15% stake in the company.

RBC Capital Markets are sole global coordinator for the offering. RBC Capital Markets and Bank Degroof Petercam are joint bookrunners.

Previous funding
Life Sciences Partners and molecular diagnostics technology business Qiagen co-led Curetis's €14.5m series-B extension in November 2014. Existing backers Aeris Capital, BioMed Invest, CD Venture, Forbion Capital Partners, HBM Partners, LSP, Roche Venture Fund, the management team, a consortium of Curetis employees, and business angels participated in the extension. Curetis stated it had raised €63.5m in total.

Company
Founded in 2007 and headquartered in Holzgerlingen, Curetis develops products for diagnosing severe infectious diseases, such as pneumonia. The company's main product is the Unyvero platform, which detects a wide range of bacteria, fungi and antibiotic resistances from a single sample.

People
Oliver Schacht is CEO of Curetis.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Exits
• Germany
• IPO